Inactive Instrument

Petlife Pharmaceuticals Inc Stock Other OTC

Equities

US71639B1052

Pharmaceuticals

End-of-day quote Other OTC
- USD - Intraday chart for Petlife Pharmaceuticals Inc
Sales 2016 - Sales 2017 - Capitalization 8.69M
Net income 2016 -3M Net income 2017 -23M EV / Sales 2016 -
Net Debt 2016 0.16 Net Debt 2017 0.66 EV / Sales 2017 -
P/E ratio 2016
-1.86 x
P/E ratio 2017
-0.37 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 90.58%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 59 18-05-29
Chief Tech/Sci/R&D Officer 65 16-06-29
Members of the board TitleAgeSince
Chief Executive Officer 59 18-05-29
More insiders
PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The Company specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. The Company has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula. The Company has rights to formulate, package and market a product line, Vitalzul. Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins and minerals. Vitalzul inhibits blood vessels formation in solid tumors. Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. As of August 31, 2016, Escozine (for humans) was sold as either a nutraceutical or prescription drug in 40 countries, including the United States.
More about the company